EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
Inc. was held on May 25, 2017. A total of 38,742,982 shares
of Emergent’s common stock was present or represented by
proxy, which represented approximately 94.6% of Emergent’s
40,956,229 shares of common stock that were outstanding and
entitled to vote at the annual meeting as of the record date
of March 29, 2017. Stockholders considered the four proposals
outlined below, each of which is described in more detail in
the proxy statement.
Kathryn C. Zoon, Ph.D. as a Class I director to hold office
for a term expiring at our 2019 annual meeting of
stockholders and (ii) each of Zsolt Harsanyi, Ph.D., General
George Joulwan (Ret.) and Louis W. Sullivan, M.D. to hold
office for a term expiring at our 2020 annual meeting of
stockholders and, in each case, until their respective
successors are duly elected and qualified. The voting results
were as follows:
|
Director Nominee
|
For
|
Withheld
|
Abstaining
|
Broker Non-Votes
|
|
Class I Director
|
||||
|
Kathryn C. Zoon, Ph.D.
|
36,602,076
|
226,851
|
8,086
|
1,905,969
|
|
Class II Directors
|
||||
|
Zsolt Harsanyi, Ph.D.
|
36,575,088
|
250,745
|
11,180
|
1,905,969
|
|
General George Joulwan (Ret.)
|
36,568,863
|
256,934
|
11,216
|
1,905,969
|
|
Louis W. Sullivan, M.D.
|
34,949,855
|
1,879,269
|
7,889
|
1,905,969
|
Registered Public Accounting Firm for the fiscal year ending
December 31, 2016. Proposal 2 was approved. The voting
results were as follows:
|
For
|
Against
|
Abstaining
|
Broker Non-Votes
|
|
38,658,182
|
74,032
|
10,768
|
N/A
|
Proposal 3 was approved. The voting results were as follows:
|
For
|
Against
|
Abstaining
|
Broker Non-Votes
|
|
33,637,108
|
3,181,353
|
18,552
|
1,905,969
|
Votes to Approve Executive Compensation. The voting results
were as follows:
|
One Year
|
Two Years
|
Three Years
|
Abstaining
|
Broker Non-Votes
|
|
323,271,692
|
15,177
|
4,544,303
|
5,841
|
1,905,969
|
own recommendation, the Board of Directors has determined to
continue to provide Emergent’s stockholders with an annual
advisory vote to approve executive compensation until the next
vote on the frequency of such advisory votes.
About EMERGENT BIOSOLUTIONS INC. (NYSE:EBS)
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity. EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Recent Trading Information
EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) closed its last trading session down -0.09 at 30.20 with 231,315 shares trading hands.